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Table e-1 Demographics Parkinson’s disease dementia vs those without dementia 
 
 PD no dementia PD dementia  
 
N= 14 N= 21 
 
Age 72.5 (5.3) 74.7 (4.7) t34=-1.33 ; p=0.191 
Female (%) 3 (20%) 3 (14%) χ2=0.21; p=0.650 
Years education 11.3 (1.9) 11.3 (1.9) t34=0.04 ; p=0.970 
Duration of Parkinson’s 10.6 (8.4) 10.0 (5.7) t34=0.22 ; p=0.827 
Levodopa dose in 24 hours 591.7 (336.2) 767.4 (464.2) t34=-1.25 ; p=0.220 
ChEI 0 (0%) 10 (48%) χ2=9.9;  p=0.002  * 
Anti-psychotics 0 (0%) 3 (14%) χ2=2.3;  p=0.126 
UPDRS III total score 34.9 (23.7) 51.8 (17.4) t34=-2.46 ; p=0.019  * 
CAMCOG total score 89.1 (6.3) 73.2 (14.5) t34=3.96 ; p=0.000  * 
MMSE score 27.3 (2.4) 22.3 (4.8) t34=3.73 ; p=0.001  * 
Angle test 21.4 (20.4) 32.4 (25.8) t32=-1.35 ; p=0.187 
Motion test -0.2 (2.9) 3.4 (2.0) t32=-4.26 ; p<0.001  * 
Best visual acuity decimal  1.2 (0.4) 0.8 (0.4) t32=3.52 ; p=0.001  * 
Pareidolia noise task  2.6 (4.8) 5.8 (4.4) t34=-2.05 ; p=0.048  * 
NPI total (AxB) 
hallucinations 0.5 (0.9) 2.6 (2.7) t34=-2.84 ; p=0.007  * 
NPI TOTAL score 5.4 (4.5) 20.1 (16.4) t31=-3.02 ; p=0.005  * 
CAF total 1.4 (2.2) 5.3 (3.7) t33=-3.54 ; p=0.001  * 
MAYO total 1.1 (1.3) 2.4 (1.2) t33=-3.09 ; p=0.004  * 
 
Data are mean (SD) or N(%). * indicates p < 0.05 
CAF= clinical assessment of fluctuations scale; CAMCOG= Cambridge Cognitive 
Examination; 
ChEI = Cholinesterase Inhibitor; MAYO= Mayo Fluctuation Composite Score; MMSE=Mini 
Mental State Exam; NPI=Neuropsychiatric inventory; PD = Parkinson’s Disease; UPDRS III 
= Unified Parkinson’s disease rating scale, motor subsection. The pareidolia task result is the 







Table e-2 VBM results 
 
Control > PD-VH  
cluster cluster 
size (vox) 
cluster  voxel xyz (mm) 
 
p 
(FWE)  p(unc) T   
0.000 6153 0.000 4.995 46.5, 13.5, -30.0 R Temporal pole 
   4.948 61.5, 4.5, 0.0  
   4.911 42.0, 7.5, -34.5  
0.018 1128 0.003 4.660 24.0, -70.5, -15.0 27% R V4, 26% FG1, 16% V3v 
   4.067 21.0, -78.0, -9.0  
   3.719 39.0, -49.5, -27.0  
0.011 1278 0.002 4.557 7.5, -60.0, 15.0 R calcarine gyrus / precuneus 
   4.377 -9.0, -60.0, 19.5  
   4.105 3.0, -57.0, 7.5  
0.084 696 0.016 4.466 13.5, 45.0, -7.5  
   4.418 3.0, 34.5, -9.0  
0.125 593 0.024 4.071 -27.0, -10.5, -15.0 L amygdala/hippocampus 
   3.679 -33.0, -24.0, -10.5  
            PD-non > PD-VH  
0.014 1212 0.002 4.396 54.0, 9.0, -27.0 R Temporal pole 
   4.204 39.0, 10.5, -39.0  
   4.082 49.5, -6.0, -27.0  
            PD-non > PD-VH controlling for Camcog  
0.041 892 0.007 4.318 55.5, 10.5, -27.0 R Temporal pole 
   4.086 39.0, 10.5, -39.0  
   3.891 39.0, 21.0, -42.0  
                              GABA-GM (controlling for age and con/PD/PD-VH)  
0.080 682 0.014 4.828 4.5, -69.0, 7.5 66% R V1, 22% RV2 
   4.181 10.5, -69.0, -1.5  




Supplementary figure e-1 
A Typical location of the MEGA-PRESS voxel. B, Edited spectrum, including the GABA peak 
for quantification at 3 ppm. C, Expanded view of B, showing 3 ppm GABA peak and fitted 





Supplementary figure e-2 
Activation and deactivation to the checkerboard stimulus in A) controls, B) PD-nonVH, C) 
PD-VH. Voxelwise threshold of p<0.001 uncorrected for multiple comparisons.
 
Supplementary Figure e-3 Group differences from TBSS analysis of diffusion data. A) 
regions where FA is lower in PD-VH vs controls B) MD is higher in PD-VH vs controls; 
Subject age was included as a covariate. 
(radiological convention – L = R) 
 
 
Supplementary figure e-4 
Grey matter correlates of GABA+/Cr. Results are thresholded with p<0.001 voxelwise 
(uncorrected for multiple comparisons). None of the clusters was significant (p > 0.05 FWE 
corrected) 
 
